We welcome you to explore our comprehensive publications database. All publications are available to download. Please select one or more fields from the list below to help narrow your search.
Date
Title
Lead Author
Drug
Conference
Download
October 23 2024
Improvements in no evidence of disease activity with ublituximab vs. teriflunomide in the ULTIMATE phase 3 studies in relapsing multiple sclerosis
Comparison of Multiple Sclerosis Disease Activity (MSDA) Test Results Between Patients Treated with Ublituximab and Teriflunomide in the Phase 3 ULTIMATE I and II Studies
Foley J, et al.
ublituximab (TG-1101)
European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
Ublituximab Significantly Reduces Radiological Disease Activity at 12 Weeks: Post-hoc analysis of Participants with Highly Active Disease in the ULTIMATE I & II Phase 3 Studies
Robertson D, et. al
ublituximab (TG-1101)
American Academy of Neurology Annual Meeting (AAN)
Disease Activity Score and Disease Pathway Scores Measured Using the Multiple Sclerosis Disease Activity Test are Significantly Reduced Prior to the Week 96 Dose for Patients Treated with Ublituximab in the Phase 3 ULTIMATE I and II Studies
Foley J, et al.
ublituximab (TG-1101)
European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
Evaluating the Maintenance of Efficacy and Tolerability when Transitioning from IV anti-CD20 Therapy to Ublituximab: ENHANCE Study Design, Patient Demographics and Preliminary Data
Foley J, et al.
ublituximab (TG-1101)
European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
Disease Outcomes With Ublituximab in Participants With Highly Active Disease: Subpopulation Analyses of the Phase 3 ULTIMATE I and II Studies in Participants With Relapsing Multiple Sclerosis
Alvarez E, et al.
ublituximab (TG-1101)
American Academy of Neurology Annual Meeting (AAN)
Onset and Maintenance of No Evidence of Disease Activity With Ublituximab: Analyses of the Phase 3 ULTIMATE I and II Studies in Participants With Relapsing Multiple Sclerosis
Alvarez E, et al.
ublituximab (TG-1101)
Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)
Functional Systems Scores and Expanded Disability Status Scale Score Evaluations in the ULTIMATE I and II Studies of Ublituximab Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis
Cree B, et al.
ublituximab (TG-1101)
European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
Disability Changes in the Absence of Relapse in the Phase 3 ULTIMATE I and II Studies of Ublituximab Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis
Wray Sibyl, et al.
ublituximab (TG-1101)
European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
Disease Outcomes With Ublituximab in Treatment-Naive Participants: Subpopulation Analyses of the Phase 3 ULTIMATE I and II Studies in Participants With Relapsing Multiple Sclerosis
Steinman L, et al.
ublituximab (TG-1101)
European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
B-Cell Depletion and Return in Participant Subgroups of the Phase 3 ULTIMATE I and II Studies of Ublituximab Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis
Fox E, et al.
ublituximab (TG-1101)
European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
Relapse Rate and Time to First Relapse were Improved with Ublituximab vs Teriflunomide in the Phase 3 ULTIMATE I and ULTIMATE II Studies in Patients with Relapsing Multiple Sclerosis (RMS)
Steinman L, et al.
ublituximab (TG-1101)
American Academy of Neurology Annual Meeting (AAN)
Disability Improvements with Ublituximab in Relapsing Multiple Sclerosis (RMS): Expanded Disability Status Scale (EDSS), 9-Hole Peg Test (9-HPT), and Timed 25-Foot Walk (T25FW) Evaluations from the Phase 3 ULTIMATE I and II Studies
Cree B, et al.
ublituximab (TG-1101)
American Academy of Neurology Annual Meeting (AAN)
Ublituximab Treatment is Associated with a Significant Proportion of Patients Achieving No Evidence of Disease Activity (NEDA): Results from the Ultimate I and Ultimate II Phase 3 Studies of Ublituximab vs Teriflunomide in Relapsing Multiple Sclerosis (RMS)
Alvarez E, et al.
ublituximab (TG-1101)
American Academy of Neurology Annual Meeting (AAN)
Infusion-Related Reactions (IRRs) with Ublituximab in Patients with Relapsing Multiple Sclerosis (RMS): Post Hoc Analyses from the Phase 3 ULTIMATE I and II Studies
Fox E, et al.
ublituximab (TG-1101)
American Academy of Neurology Annual Meeting (AAN)
Pharmacodynamics of B-Cell Depletion and Pharmacokinetics of the Novel Anti-CD20 Monoclonal Antibody Ublituximab in Patients with Relapsing Multiple Sclerosis
Fox E, et al.
ublituximab (TG-1101)
Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)
Efficacy and Safety of Ublituximab in Combination with Umbralisib (U2) in Patients with Chronic Lymphocytic Leukemia (CLL) by Treatment Status: A Sub-analysis of the Phase 3 UNITY-CLL Study
A Phase 2 Study Evaluating the Addition of Ublituximab and Umbralisib (U2) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL): a Minimal Residual Disease (MRD)-driven, Time-limited Approach
Efficacy and Safety of Umbralisib and Ublituximab (U2), and U2 Plus Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
The Combination of Umbralisib Plus Ublituximab is Active in Patients with Relapsed or Refractory Marginal Zone Lymphoma (MZL): Results from the Phase 2 Global UNITY-NHL Trial
The Selective Bruton’s Tyrosine Kinase (BTK) Inhibitor TG-1701 as Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients with B-cell Malignancies
Ublituximab Is Associated With Significant Improvement in the Multiple Sclerosis Functional Composite (MSFC): Results From the Phase 3 ULTIMATE I & II Studies
Steinman L, et al.
ublituximab (TG-1101)
European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
TG-1701, a Selective Bruton Tyrosine Kinase (BTK) Inhibitor, as Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients with Chronic Lymphocytic Leukemia
Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment-Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 UNITY-CLL Study
Phase I/II Study of Umbralisib (TGR-1202), Ublituximab (TG-1101), and Pembrolizumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Richter’s Transformation: 5-Year Follow-up
Antitumoral Activity of the Novel BTK Inhibitor TG-1701 is Associated with Disruption of Ikaros Signaling and Improvement of Anti-CD20 Therapy in B-cell Non-Hodgkin Lymphoma
Roue G, et al.
TG-1701
International Congress on Malignant Lymphoma (ICML)
Updated Results of the Selective Bruton Tyrosine kinase (BTK) Inhibitor TG-1701, as Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients (pts) with B-cell Malignancies
Updated Results of the Selective Bruton Tyrosine Kinase (BTK) Inhibitor TG-1701, as Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients (pts) with B-cell Malignancies
Updated Results of the Selective Bruton Tyrosine Kinase (BTK) Inhibitor TG-1701, as Monotherapy and in Combination with Ublituximab and Umbralisib(U2) in Patients (pts) with B-cell Malignancies
VIDEO: Updated Results of the Selective Bruton Tyrosine Kinase (BTK) Inhibitor TG-1701, as Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients (pts) with B-cell Malignancies
Efficacy and Safety of Ublituximab vs Teriflunomide in Patients with Relapsing Multiple Sclerosis: Results from Two Phase 3 Studies ULTIMATE I & ULTIMATE II American Academy of Neurology
Steinman L, et al.
ublituximab (TG-1101)
American Academy of Neurology Annual Meeting (AAN)
Umbralisib, a PI3Kδ/CK1ε dual inhibitor demonstrates marked clinical activity in patients with relapsed or refractory indolent non-Hodgkin lymphoma: Results from the Phase 2 global UNITY-NHL trial
Zinzani P, et al.
umbralisib (TGR-1202)
American Society of Hematology Annual Meeting (ASH)
Phase 3 Study of Umbralisib Combined With Ublituximab vs Obinutuzumab Plus Chlorambucil in Patients With Chronic Lymphocytic Leukemia: Results From UNITY-CLL
VIDEO: Phase 3 Study of Umbralisib Combined With Ublituximab vs Obinutuzumab Plus Chlorambucil in Patients With Chronic Lymphocytic Leukemia: Results From UNITY-CLL
VIDEO: Umbralisib, a PI3Kδ/CK1ε dual inhibitor demonstrates marked clinical activity in patients with relapsed or refractory indolent non-Hodgkin lymphoma: Results from the Phase 2 global UNITY-NHL trial
Zinzani, P et al.
umbralisib (TGR-1202)
American Society of Hematology Annual Meeting (ASH)
Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 UNITY-CLL Study
Umbralisib, the Once Daily Dual Inhibitor of PI3Kδ and Casein Kinase-1ε Demonstrates Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: Results from the Phase 2 Global UNITY-NHL Trial
Zinzani P, et al.
umbralisib (TGR-1202)
American Society of Hematology Annual Meeting (ASH)
TG-1701, a Novel Irreversible Bruton’s Kinase (BTK) Inhibitor, Cooperates with Ublituximab-Driven ADCC and ADCP in In Vitro and In Vivo Models of Ibrutinib-Resistant Mantle Cell Lymphoma
Ribeiro M, et al.
TG-1701, ublituximab (TG-1101)
American Association for Cancer Research Annual Meeting (AACR)
Safety and Activity of the Once Daily Selective Bruton Tyrosine Kinase (BTK) Inhibitor TG-1701 in Patients with Chronic Lymphocytic Leukemia (CLL) and Lymphoma
Cheah C, et al.
TG-1701
Congress of the European Hematology Association (EHA)
Effect of Adding Ublituximab to Ibrutinib on PFS, ORR, and MRD Negativity in Previously Treated High-Risk Chronic Lymphocytic Leukemia: Final Results of the GENUINE Phase III Study
Sharman J, et al.
ublituximab (TG-1101)
American Society of Clinical Oncology Annual Meeting (ASCO)
A Phase 2 Multicenter Study of Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis
Long-term Follow-up Results From the Phase 2 Multicenter Study of Ublituximab(UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients With Relapsing Multiple Sclerosis (RMS)
Fox E, et al.
ublituximab (TG-1101)
Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)
Phase 1 Study of TG-1701, a Selective Irreversible Inhibitor of Bruton’s Tyrosine Kinase (BTK), in Patients with Relapsed/Refractory B-Cell Malignancies
A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib in Patients with Chronic Lymphocytic Leukemia (CLL) Who Are Intolerant to Prior BTK or PI3K Delta Inhibitor Therapy
Mato A, et al.
umbralisib (TGR-1202)
International Workshop on Chronic Lymphocytic Leukemia (iwCLL)
Phase I/II Triple Therapy Study of Umbralisib and Ublituximab (U2) Combined with Checkpoint Inhibition in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Richter’s Transformation (RT)
Mato A, et al.
umbralisib (TGR-1202), ublituximab (TG-1101)
International Workshop on Chronic Lymphocytic Leukemia (iwCLL)
Long-term Follow-up Results from the Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Multiple Sclerosis (RMS)
Fox E, et al.
ublituximab (TG-1101)
European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
Study Design and Patient Demographics of the ULTIMATE Phase III Trials Evaluating Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Multiple Sclerosis (RMS)
Cree B, et al.
ublituximab (TG-1101)
European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
Open Label Extension (OLE) of Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Forms of Multiple Sclerosis (RMS)
Fox E, et al.
ublituximab (TG-1101)
Congress of the European Academy of Neurology (EAN)
Phase I/II Study of Umbralisib (TGR-1202) in Combination with Ublituximab (TG-1101) and Pembrolizumab in Patients with Relapsed/Refractory CLL and Richter’s Transformation
Mato A, et al.
umbralisib (TGR-1202), ublituximab (TG-1101)
International Congress on Malignant Lymphoma (ICML)
A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib in Patients with Chronic Lymphocytic Leukemia (CLL) Who Are Intolerant to Prior BTK or PI3K Delta Inhibitor Therapy
Mato A, et al.
umbralisib (TGR-1202)
International Congress on Malignant Lymphoma (ICML)
Umbralisib Monotherapy Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Registration Directed Phase 2 Study
Zinzani P, et al.
umbralisib (TGR-1202)
International Congress on Malignant Lymphoma (ICML)
The Novel Bispecific CD47-CD19 Antibody TG-1801 Potentiates the Activity of Ublituximab-Umbralisib (U2) Drug Combination in Preclinical Models of B-NHL
Ribeiro M et al.
TG-1801
Congress of the European Hematology Association (EHA)
The Novel Bispecific CD47-CD19 Antibody TG-1801 Potentiates the Activity of Ublituximab-Umbralisib (U2) Drug Combination in Preclinical Models of B-NHL
Umbralisib Monotherapy Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-label, Registration Directed Phase 2 Study
Fowler N, et al.
umbralisib (TGR-1202)
American Society of Clinical Oncology Annual Meeting (ASCO)
Open Label Extension (OLE) of a Phase 2 Multicenter Study Of Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Forms of Multiple Sclerosis (RMS)
Fox E, et al.
ublituximab (TG-1101)
American Academy of Neurology Annual Meeting (AAN)
TG Therapeutics Reports Positive Interim Data from UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Marginal Zone Lymphoma at the 2019 AACR Annual Meeting
Fowler N, et al.
umbralisib (TGR-1202)
American Association for Cancer Research Annual Meeting (AACR)
Final Results of a Phase 2 Multicenter Study of Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Patients with Relapsing Forms of Multiple Sclerosis (RMS)
Fox E, et al.
ublituximab (TG-1101)
Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)
Tolerability and Activity of Ublituximab, Umbralisib, and Ibrutinib in Patients with Chronic Lymphocytic Leukaemia and Non-Hodgkin Lymphoma: A Phase 1 Dose Escalation and Expansion Trial
Umbralisib in Combination with Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukaemia or Mantle Cell Lymphoma: A Multicentre Phase 1–1b Study
Phase I/II Study of Umbralisib (TGR-1202) in Combination with Ublituximab (TG-1101) and Pembrolizumab in Patients with Relapsed/Refractory CLL and Richter’s Transformation
Mato A, et al.
umbralisib (TGR-1202), ublituximab (TG-1101)
American Society of Hematology Annual Meeting (ASH)
Final Results of a Placebo Controlled, Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Forms of Multiple Sclerosis (RMS)
Fox E, et al.
ublituximab (TG-1101)
European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
Phase 2 Multicenter Study Results of Ublituximab, a Novel Glycoengineered AntiCD20 Monoclonal Antibody (mAb), in Patients with Relapsing Multiple Sclerosis (RMS)
Fox E, et al.
ublituximab (TG-1101)
Congress of the European Academy of Neurology (EAN)
A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib (TGR-1202) in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K Delta Inhibitor Therapy
Mato A, et al.
umbralisib (TGR-1202)
Congress of the European Hematology Association (EHA)
Long Term Integrated Safety Analysis Of Umbralisib (TGR-1202), A PI3K?/Ck1? Inhibitor With A Differentiated Safety Profile, In Patients With Relapsed/Refractory Lymphoid Malignancies
Davids M, et. al.
umbralisib (TGR-1202)
Congress of the European Hematology Association (EHA)
A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib (TGR-1202) in Patients with CLL who are Intolerant to Prior BTK or PI3K Inhibitor Therapy
Mato A, et al.
umbralisib (TGR-1202)
American Society of Clinical Oncology Annual Meeting (ASCO)
Final MRI Results at 6 Months from a Phase 2 Multicenter Study of Ublituximab, A Novel Glyocoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Forms of Multiple Sclerosis (RMS), Demonstrates Complete Elimination of Gd-Enhancing Lesions
Inglese M, et al.
ublituximab (TG-1101)
American Academy of Neurology Annual Meeting (AAN)
Umbralisib, a Novel PI3Kδ and Casein Kinase-1ε Inhibitor, in Relapsed or Refractory Chronic Lymphocytic Leukaemia and Lymphoma: an Open-label, Phase 1, Dose-escalation, First-in-human Study
KI Intolerance Study: A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib (TGR-1202) in Patients with Chronic Lymphocytic Leukemia (CLL) Who Are Intolerant to Prior BTK or PI3K Delta Inhibitor Therapy
Mato A, et al.
umbralisib (TGR-1202)
American Society of Hematology Annual Meeting (ASH)
An Integrated Safety Analysis of the Next Generation PI3K Delta Inhibitor Umbralisib (TGR-1202) in Patients with Relapsed/Refractory Lymphoid Malignancies
Davids M, et al.
umbralisib (TGR-1202)
American Society of Hematology Annual Meeting (ASH)
Placebo controlled, phase 2a multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis (RMS): 6 months analysis of B cell subsets
Lovett-Racke A, Fox E, et al.
ublituximab (TG-1101)
European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
Patient characteristics, safety, and preliminary results of a placebo controlled, phase 2a multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis
Fox E, et al.
ublituximab (TG-1101)
European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
Preliminary results of phase 2 multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis (RMS) demonstrates rapid Gd-enhancing lesions decrease
Inglese M, et al.
ublituximab (TG-1101)
European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
Rapid and Robust B Cell Depletion in Preliminary Results of Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing forms of Multiple Sclerosis (RMS)
Fox E, et al.
ublituximab (TG-1101)
Congress of the European Academy of Neurology (EAN)
Updated Results of a Multicenter Phase I/IB Study of Umbralisib (TGR-1202) in Combination with Ibrutinib in Patients with Relapsed or Refractory MCL or CLL
Davids M, et al.
umbralisib (TGR-1202)
International Congress on Malignant Lymphoma (ICML)
Preliminary results of Phase 2 Multicenter Study of Ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of Multiple Sclerosis (RMS) demonstrates rapid and robust B cell depletion
Lovett-Racke A, Fox E et al.
ublituximab (TG-1101)
American Academy of Neurology Annual Meeting (AAN)
KI intolerance study: A phase 2 study to assess the safety and efficacy of TGR-1202 in pts with chronic lymphocytic leukemia (CLL) who are intolerant to prior BTK or PI3K-delta inhibitor therapy
Dorsey, Mato, et al.
umbralisib (TGR-1202)
American Society of Clinical Oncology Annual Meeting (ASCO)
Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial
A phase 1/2 trial of ublituximab, a novel, glycoengineered anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab
A Phase I Trial of TGR-1202, a Next Generation Once Daily PI3K Delta Inhibitor, in Combination with Brentuximab Vedotin, in Patients with Relapsed/Refractory Hodgkins Lymphoma
Ramchandran et al.
umbralisib (TGR-1202)
American Society of Hematology Annual Meeting (ASH)
Long-term follow-up of the PI3K delta inhibitor TGR-1202 demonstrates a differentiated safety profile and high response rates in CLL and NHL: Integrated-analysis of TGR-1202 monotherapy and combined with ublituximab.
Burris H, Flinn I, et al.
umbralisib (TGR-1202)
American Society of Clinical Oncology Annual Meeting (ASCO)
Long-term follow-up of PI3K delta inhibitor TGR-1202 demonstrates safety and high response rates in NHL: Integrated Analysis of TGR-1202 monotherapy and combined with ublituximab
O'Connor O, et al.
umbralisib (TGR-1202)
Congress of the European Hematology Association (EHA)
Long-term follow-up of the PI3k delta inhibitor TGR-1202 demonstrates a differentiated safety profile and high response rates in CLL: Integrated-analysis of TGR-1202 monotherapy and commbined with ublituximab.
Mato A, et al.
umbralisib (TGR-1202)
Congress of the European Hematology Association (EHA)
Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib is Highly Active in Patients with Relapsed and/or Refractory Mantle Cell Lymphoma: Results of a Phase II Trial.
Sharman J, et al.
ublituximab (TG-1101)
American Society of Hematology Annual Meeting (ASH)
Disruption of the mTOR-eIF4F Axis By Selectively Targeting PI3Kdelta and Proteasome Potently Inhibits Cap Dependent Translation of c-Myc in Aggressive Lymphomas.
Deng C, et al.
umbralisib (TGR-1202)
American Society of Hematology Annual Meeting (ASH)
A Phase I Trial of TGR-1202, a Next Generation Once Daily PI3K-Delta Inhibitor in Combination with Obinutuzumab Plus Chlorambucil, in Patients with Chronic Lymphocytic Leukemia.
Mahadevan D, et al.
umbralisib (TGR-1202)
American Society of Hematology Annual Meeting (ASH)
Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib is Highly Active in Patients with Relapsed and/or Refractory Mantle Cell Lymphoma: Results of a Phase II Trial.
SharmanJ, et al.
ublituximab (TG-1101)
American Society of Hematology Annual Meeting (ASH)
a Novel Once Daily PI3K-Delta Inhibitor, Demonstrates Clinical Activity with a Favorable& Differentiated Safety Profile as a Single Agent and in Combination with a Novel Glyocengineered anti-CD20 mAb, Ublituximab in Patients with Rel/Ref CLL.
O'Brien, et al.
ublituximab (TG-1101)
International Workshop on Chronic Lymphocytic Leukemia (iwCLL)
Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 MAB, in Combination with Ibrutinib Achieves 95% ORR in Patients with High-Risk Relapsed/Refractory CLL.
Burke J, et al.
ublituximab (TG-1101)
International Congress on Malignant Lymphoma (ICML)
Safety and Activity of the Chemotherapy-Free Triplet of Ublituximab, TGR-1202, and Ibrutinib is Safe and Highly Active in Relapsed B-Cell Malignancies.
Nastoupil L, et al.
umbralisib (TGR-1202), ublituximab (TG-1101)
International Congress on Malignant Lymphoma (ICML)
Clinical Activity and Safety Profile of TGR-1202, a Novel Once Daily PI3K-Delta Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile, Lacking Hepatotoxicity in Patients with CLL and B-Cell Lymphoma.
O'Connor, et al.
umbralisib (TGR-1202)
International Congress on Malignant Lymphoma (ICML)
Clinical Activity and Safety Profile of TGR-1202 a Novel Once Daily PI3K-Delta Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile, Lacking Hepatotoxicity, in Patients with CLL and B-Cell Lymphoma.
O'Connor, et al.
umbralisib (TGR-1202)
Congress of the European Hematology Association (EHA)
Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Combination with TGR-1202, a Next Generation Once Daily PI3K Delta Inhibitor, Demonstrate Activity in Heavily Pre-Treated and High-Risk Chronic Lymphocytic Leukemia (CLL) and B-Cell Lymphoma.
Lunning M, O'Brien S, et al.
umbralisib (TGR-1202), ublituximab (TG-1101)
American Society of Hematology Annual Meeting (ASH)
Ublituximab (TG-1101) a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib is Highly Active in Patients with Relapsed and/or Refractory CLL and MCL: Results of a Phase II Trial.
Sharman J, Greenwald D, et al.
ublituximab (TG-1101)
American Society of Hematology Annual Meeting (ASH)
TGR-1202, a Novel Once Daily Pi3K Delta Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile, Lacking Hepatotoxicity, in Patients with Chronic Lymphocytic Leukemia and B-Cell Lymphoma.
Burris H, Flinn I, et al.
umbralisib (TGR-1202)
American Society of Hematology Annual Meeting (ASH)
The PI3K-delta Inhibitor TGR-1202 in Combination with Brentuximab Vedotin (SGN-35) Synergistically Inhibits Tubulin Polymerization and Exerts Potent Antitumor Effects in NOD/SCID Mice with Hodgkin Lymphoma Cell Line Xenografts.
Locatelli, et al.
umbralisib (TGR-1202)
American Society of Hematology Annual Meeting (ASH)
A Phase I Trial of Ublituximab, A Novel Glycoengineered Anti-CD20 mAb, In Combination With TGR-1202, A Next Generation PI3K Delta Inhibitor, In Patients With Chronic Lymphocytic Leukemia And Non-Hodgkin’s Lymphoma.
Ublituximab (TG-1101), A Novel Glycoenginereed Anti-CD20 mAb, in Combination with Ibrutinib in Patients with CLL and MCL; Results of an Ongoing Phase II Trial.
Sharman J, O'Connor O, et. al.
ublituximab (TG-1101)
Congress of the European Hematology Association (EHA)
The PI3K Delta Inhibitor TGR-1202 In Combination with Brentuximab Vedotin (SGN-35) Synergistically Induces G2/M Phase Arrest and Cell Death Via Inhibition of Tubulin Polymerization in Hodgkin Lymphoma Cell Lines.
Locatelli S, Carlo-Stella C, et al.
umbralisib (TGR-1202)
American Association for Cancer Research Annual Meeting (AACR)
The PI3K-d Inhibitor TGR-1202 in Combination with Brentuximab Vedotin (SGN-35) Synergistically Induces G2/M Phase Arrest and Cell Death Via Inhibition Of Tubulin Polymerization in Hodgkin Lymphoma Cell Lines.
Locatelli S, Carlo-Stella C, et al.
umbralisib (TGR-1202)
American Society of Hematology Annual Meeting (ASH)
Final Results of a Multicenter Phase Ib Single Agent Study with the Novel Anti-CD20 Monoclonal Antibody Ublituximab (TG-1101) in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL).
Cazin B, Ribrag V, et al.
ublituximab (TG-1101)
Congress of the European Hematology Association (EHA)
A Phase I Dose-Escalation Trial of Ublituximab (TG-1101), a Novel Anti-CD20 Monoclonal Antibody (mAb) for Rituximab Relapsed and/or Refractory C-Cell Lymphoma Patients.
Changchun D, O'Connor O, et al.
ublituximab (TG-1101)
American Society of Clinical Oncology Annual Meeting (ASCO)
Novel PI3K Inhibitors Demonstrate Marked Cytotoxicity in Models of T-Cell Lymphoma, Caused Apoptosis and Were Synergistic with the Novel Anti-CD20 Monoclonal Antibody Ublituximab in Models of B-Cell Lymphoma
Deng, Changchun
umbralisib (TGR-1202)
International Congress on Malignant Lymphoma (ICML)
Ublituximab (TGTX-1101), A Novel Anti-CD20 Monoclonal Antibody (mAb), Demonstrates Activity in Rituximab-sensitive and Rituximab–resistant B Non-Hodgkin Lymphoma (B-NHL) Pre-clinical In Vitro and In Vivo Models.
Barth M, Czuczman M, et al.
ublituximab (TG-1101)
American Society of Hematology Annual Meeting (ASH)
Ublituximab, an Optimized Anti-CD20 Monoclonal Antibody, Demonstrates Greater NK-Mediated ADCC Than Rituximab in Waldenstrom’s Macroglobulinemia Patients Supporting a Therapeutic Strategy with Ublituximab.
Le Garff-Tavernier M, Leblond V, et al.
ublituximab (TG-1101)
American Society of Hematology Annual Meeting (ASH)
Novel PI3K Inhibitors Demonstrate Marked Cytotoxicity in Models of T-Cell Lymphoma, Caused Apoptosis and Were Synergistic with the Novel Anti-CD20 Monoclonal Antibody Ublituximab in Models of B-Cell Lymphoma
Changchun D, O'Connor O, et al.
umbralisib (TGR-1202)
American Society of Hematology Annual Meeting (ASH)
Multicentre Phase I Study with an 8-Dose Regimen of Single Agent Anti-CD20 Monoclonal Antibody LFB-R603 in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL).
Cazin B, Coiffier B, Cartron G, et al.
ublituximab (TG-1101)
American Society of Hematology Annual Meeting (ASH)
You are now leaving TGTherapeutics.com, a website wholly owned and operated by TG Therapeutics, Inc. This link will take you to a website to which this Privacy Policy does not apply. TG Therapeutics, Inc., does not endorse or influence the content of websites that are not owned or operated by TG Therapeutics, Inc.
